Risk factors for potential drug–drug interactions in patients with myasthenia gravis

References

• Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–425.
   PubMed Web of Science ®Google Scholar
• Lavrnic D, Basta I, Rakocevic-Stojanovic V, et al. Epidemiological study of adult-onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979-2008. Neuroepidemiology. 2013;40(3):190‐194.
   PubMed Web of Science ®Google Scholar
• Basta I, Pekmezović T, Perić S, et al. Survival and mortality of adult-onset myasthenia gravis in the population of Belgrade, Serbia. Muscle Nerve. 2018;58(5):708‐712.
   PubMed Web of Science ®Google Scholar
• Farmakidis C, Pasnoor M, Dimachkie MM, et al. Treatment of myasthenia gravis. Neurol Clin. 2018;36(2):311–337.
   PubMed Web of Science ®Google Scholar
• Cai XJ, Li ZW, Xi JY, et al. Myasthenia gravis and specific immunotherapy: monoclonal antibodies. Ann N Y Acad Sci. 2019;1452(1):18–33.
   PubMed Web of Science ®Google Scholar
• Schneider-Gold C, Hagenacker T, Melzer N, et al. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.
   Web of Science ®Google Scholar
• Cascorbi I. Drug interactions--principles, examples and clinical consequences. Dtsch Arztebl Int. 2012;109(33–34):546–556.
   PubMed Web of Science ®Google Scholar
• Kheshti R, Aalipour M, Namazi S. A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257–263.
   PubMed Web of Science ®Google Scholar
• Zeitler K, Jariwala R, Montero J. Adverse events releated to antibiotic use in patients with myasthenia gravis. Open Forum Infect Dis. 2017;4(Suppl 1):S342.
   Google Scholar
• Jordan H, Ortiz N. Management of Insomnia and anxiety in myasthenia gravis. J Neuropsychiatry Clin Neurosci. 2019;31(4):386–391.
   PubMed Web of Science ®Google Scholar
• Gummi RR, Kukulka NA, Deroche CB, et al. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve. 2019;60(6):693–699.
   PubMed Web of Science ®Google Scholar
• Ogutlu H, Karayagmurlu A, Esin IS, et al. Myasthenia gravis attack after oral risperidone treatment: a case report. Eurasian J Med. 2018;50(2):128–129.
   PubMed Web of Science ®Google Scholar
• Pina Latorre MA, Cobeta JC, Rodilla F, et al. Influence of calcium antagonist drugs in myasthenia gravis in the elderly. J Clin Pharm Ther. 1998;23(5):399–401.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.
   PubMed Web of Science ®Google Scholar
• Jaretzki A 3rd, RJ B, Rm E, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology. 2000;55(1):16‐23. .
   PubMed Web of Science ®Google Scholar
• Busa G, Burlina A, Damuzzo V, et al. Comorbidity, polytherapy, and drug interactions in a neurological context: an example of a multidisciplinary approach to promote the rational use of drugs. J Pharm Pract. 2018;31(1):58–65.
   PubMed Web of Science ®Google Scholar
• Namazi S, Pourhatami S, Borhani-Haghighi A, et al. Incidence of potential drug-drug interaction and related factors in hospitalized neurological patients in two iranian teaching hospitals. Iran J Med Sci. 2014;39(6):515–521.
   PubMedGoogle Scholar
• Zafar R, Chisthi K, Zahoor M. Potential drug-drug interactions in the neurology ward of a tertiary care hospital in Peshawar, Pakistan. Trop J Pharm Res. 2017;16(10):2521–2526.
   Web of Science ®Google Scholar
• Yasir M, Goyal A, Bansal P, et al. Corticosteroid adverse effects. [Updated 2020 Apr 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531462/.
   Google Scholar
• Sathasivam S. Current and emerging treatments for the management of myasthenia gravis. Ther Clin Risk Manag. 2011;7:313–323.
   PubMed Web of Science ®Google Scholar
• Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci. 2006;9(3):427–433.
   PubMed Web of Science ®Google Scholar
• Bethi Y, Shewade DG, Dutta TK, et al. Prevalence and predictors of potential drug-drug interactions in patients of internal medicine wards of a tertiary care hospital in India. Eur J Hosp Pharm. 2018;25(6):317–321.
   PubMedGoogle Scholar
• Lin C-F, Wang C-Y, Bai C-H. Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan. Drugs Aging. 2011;28(3):219–225.
   PubMed Web of Science ®Google Scholar
• Li V, Jasinarachchi M, Butler E. Epidemiology, symptomatology and treatment of patients with myasthenia gravis in an Australian hospital. Intern Med J. 2019;49(12):1537–1540.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Khan MU, Haque I, et al. Evaluation of potential drug - drug interactions in general medicine ward of teaching hospital in southern India. J Clin Diagn Res. 2015;9(2):FC10–FC13.
   PubMed Web of Science ®Google Scholar
• Nusair MB, Al-Azzam SI, Arabyat RM, et al. Theprevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan. Saudi Pharm J. 2020;28(2):155–160.
   PubMed Web of Science ®Google Scholar
• Bose D, Pattern SM. predictors of drug-drug interactionsamong the patients admitted in neurology at a tertiary care hospital – a cross-sectional study. Int J Pharm Sci Res. 2016;7(8):3458–3464.
   Web of Science ®Google Scholar
• Campen CJ, Vogel WH, Shah PJ. Managing drug interactions in cancer therapy: a guide for the advanced practitioner. J Adv Pract Oncol. 2017;8(6):609‐620.
   Google Scholar
• Basta I, Pekmezovic T, Peric S, et al. Extrathymic malignancies in a defined cohort of patients with myasthenia gravis. J Neurol Sci. 2014;346(1–2):80‐84.
   PubMed Web of Science ®Google Scholar
• Grassi G, Robles NR, Seravalle G, et al. Lercanidipine in the management of hypertension: an update. J Pharmacol Pharmacother. 2017;8(4):155‐165.
   PubMed Web of Science ®Google Scholar
• Gossmann J, Kachel HG, Schoeppe W, et al. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation. 1993;56(3):585‐589.
   Web of Science ®Google Scholar
• Gossmann J, Thürmann P, Bachmann T, et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int. 1996;50(3):973‐978.
   PubMed Web of Science ®Google Scholar
• Weir MR, Gravens-Muller L, Costa N, et al. Safety events in kidney transplant recipients: results from the folic acid for vascular outcome reduction in transplant trial. Transplantation. 2015;99(5):1003‐1008.
   Web of Science ®Google Scholar
• Mandaliya R, Kulandaivel K, Nowotarski N, et al. Diagnosis of fluctuating dyspnea: myasthenia gravis. J Clin Diagn Res. 2015;9(6):OD06–OD8.
   PubMed Web of Science ®Google Scholar
• DeSilvaP W, Havard CWH. Plasma pyridostigmine levels in myasthenia gravis. Neurology(Ny). 1981;31(2):145–150.
   PubMed Web of Science ®Google Scholar
• Benatar M, Mcdermott MP, Sanders DB, et al. Muscle Study Group (MSG). Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016;53(3):363–369.
   PubMed Web of Science ®Google Scholar
• Shakeel F, Aamir M, Khan AF, et al. Epidemiology of potential drug-drug interactions in elderly population admitted to critical care units of Peshawar, Pakistan. BMC Pharmacol Toxicol. 2018;19(1):85.
   PubMedGoogle Scholar
• Nishandar TB, Kale AS, Pise HN. Study of potential drug interactions between prescribed drugs in geriatric patients attending outpatient department in a government tertiary care hospital in Maharashtra. Int J Basic Clin Pharmacol. 2016;5(4):1569–1573.
   Google Scholar